KINIKSA A BE-,000273235 Logo
BMG5269C1010
A2JMVJ
KNSA

KINIKSA A BE-,000273235

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 84,34 (-3,49%). A mediana é € 89,33 (+2,22%).

Comprar
  11
Manter
  0
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline

    Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Mais em de.investing.com


  • Kiniksa Pharmaceuticals reaches record high at $64.85

    Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Mais em de.investing.com


  • Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%

    Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Mais em de.investing.com


  • Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance

    Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Mais em de.investing.com


  • Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket

    Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, KINIKSA A BE-,000273235 registou receitas de € 252,47 mi e um ganho líquido de € 41,8 mi
(EUR) setembro de 2026
YoY
Receitas 252,47 mi 63,82%
Ganho bruto 134,53 mi 62,32%
Ganho líquido 41,8 mi 166,08%
EBITDA 52,57 mi 124,01%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 6,86 bi
Número de ações
78,57 mi
Máximo/mínimo de 52 semanas
€ 90,06 - € 33,57
Dividendos Não
Beta
0,08
PER (PE Ratio)
67,36
PEG (PEG Ratio)
0,35
P/VC (PB Ratio)
10,61
P/V (PS Ratio)
8,00

Perfil da empresa

A Kiniksa Pharmaceuticals, Ltd., uma empresa biofarmacêutica, dedica-se à descoberta, aquisição, desenvolvimento e comercialização de medicamentos terapêuticos para doentes com doenças debilitantes e necessidades médicas não satisfeitas significativas a nível mundial. Os seus candidatos a medicamento incluem o ARCALYST, uma interleucina-1alfa e interleucina-1beta, para o tratamento da pericardite recorrente, que é uma doença cardiovascular inflamatória; o Mavrilimumab, um inibidor de anticorpo monoclonal que concluiu os ensaios clínicos de Fase II para o tratamento da arterite de células gigantes; o Vixarelimab, um anticorpo monoclonal, que se encontra em ensaio clínico de Fase 2a para o tratamento do prurigo nodular, uma doença inflamatória crónica da pele; e o KPL-404, um inibidor de anticorpo monoclonal da interação CD40-CD154, um sinal coestimulador das células T crítico para a maturação das células B, a mudança de classe das imunoglobulinas e a resposta imunitária do tipo 1. A Kiniksa Pharmaceuticals, Ltd. foi constituída em 2015 e tem sede em Hamilton, Bermudas.

Nome
KINIKSA A BE-,000273235
CEO
Sanj K. Patel
Sede London, gl
Bermudas
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
25/05/2018
Colaboradores 366

Símbolos de ticker

Bolsa Símbolo
NASDAQ
KNSA
🍪

Parqet  utiliza cookies. Saber mais